The U.S. Patent and Trademark Office has issued the University of Utah U.S. patent No. U.S. 6,787,338 (the '338 patent) relating to methods of rapid nucleic acid amplification. The issuance of th
The physician who revolutionized screening methods for glaucoma nearly 20 years ago has patented a new device aimed at detecting glaucoma, a leading cause of blindness. Steven Feldon, M.D., director of the Eye Institute at the
Chiron Corporation has announced that it has reached a settlement with F. Hoffmann-La Roche (Roche) in a dispute over licensing fees and royalties that Chiron had asserted was owed to the company under
Scientists from MitoChroma Research have recently announced a patent pending discovery that could complement current medical management modalities for Type 2 Diabetes, insulin resistance and the se
Nanotechnology company pSivida has announced that its UK operating subsidiary pSiMedica Limited has been granted a further patent for BioSiliconTM. European Patent Number 1309309 relates to
MorphoSys Obtains Additional U.S. Patents on Antibody Technologies MorphoSys AG (Frankfurt Stock Exchange: MOR; Prime Standard Segment) announced today that the U.S. Patent & Trademark Office has
ChemGenex Pharmaceuticals has announced that it has filed for patent protection for a further five novel depression-associated gene targets discovered by its depression and anxiety research group.
Elan Corporation and Wyeth Pharmaceuticals have announced that the United States Patent and Trademark Office recently issued Neuralab Limited, a subsidia
Vitro Diagnostics has announced the development of new methods for the growth and development of human pancreatic beta islets (Islets of Langerhans) and the filing of a new patent application with t
Competitive Technologies announced today that patent number 6,808,561 has been issued by the US Patent Office for Dr. Brian R. Genge's nanotechnology bone biomaterial developed at the Universi
Date: Friday, 21-Jul-2006
Synergetics has announced that it has received an additional patent covering its bipolar technology through the issuance of U.S. patent number 7,041,096.This patent will provide protection for this proprietary invention through 2023.
This patented technology is currently being used in the Stryker Pain Management unit and the new Malis(R) Advantage(TM). The Company plans to further use this technology in new products currently in development.
"Jerry Malis and our engineers in Philadelphia continue to lead the field in bipolar circuit technology," said Gregg D. Scheller, President and Chief Executive Officer of Synergetics USA, Inc. "This latest patent represents the pinnacle of circuit design for surgical applications of bipolar technology. It is important to Synergetics to remain the technological leader in those fields in which we participate and this patent is important in maintaining that leadership position as we move forward."
http://www.synergeticsusa.com